Kamada Expands Plasma Collection with New San Antonio Facility to Boost Therapeutic Capabilities

Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapeutics, is expanding its plasma collection capabilities with a new state-of-the-art center in San Antonio, Texas. The 11,100-square-foot facility is designed to support up to 50 donor beds and projected to collect 50,000 liters of plasma annually.

The new center represents a strategic move to enhance the company's ability to produce critical hyper-immune plasma products used in treating various medical conditions. These specialized plasma products are essential for protecting individuals who have undergone organ transplants, preventing rabies, and managing hepatitis B infections.

Kamada's CEO, Amir London, highlighted the facility's dual purpose: collecting specialty plasma for internal use and generating revenue through the sale of normal source plasma to other pharmaceutical manufacturers. Once fully operational, the center is expected to contribute between $8 million and $10 million in annual sales.

The company anticipates receiving necessary approvals from the U.S. Food and Drug Administration and European Medicines Agency within nine to twelve months. This expansion follows the company's recent opening of a similar facility in Houston and builds upon its existing plasma collection center in Beaumont, Texas.

By developing its own plasma collection infrastructure, Kamada aims to reduce its reliance on third-party suppliers, potentially lowering raw material costs and positioning itself as a significant player in the specialty plasma-derived therapeutics market. The company has already received FDA approval for six plasma-derived therapeutics targeting rare and underserved medical conditions.